The aim of this study was to characterize neuromuscular fatigue in knee extensor muscles after a prolonged cycling exercise. During the two days preceding a 140-km race (mean +/- SD duration: 278.2 +/- 24.9 min) and 15 to 30 min after, maximal percutaneous electrical stimulations were applied to the femoral nerve of 11 trained cyclists. Electrically evoked superimposed twitches and trains of 6 stimulations were delivered during isometric maximal voluntary contraction (MVC) to determine maximal voluntary activation (% VA). Knee extensors MVC decreased with fatigue from 158.2 +/- 29.6 to 144.2 +/- 30.0 Nm (p < 0.01), but no central activation failure was detected after the race. The average rate of twitch force development increased significantly from 414 +/- 106 to 466 +/- 102 N x m x s-1 (p < 0.05) and a tendency toward higher peak twitch tension (p = 0.052) was found in the fatigued state. Short tetanus at 20 Hz and 80 Hz were also applied to 4 cyclists, but these fused and unfused tetanic forces were not significantly modified with fatigue. From these results, it can be concluded that the small but significant isometric strength loss measured less than 30 min after the end of a long distance road cycling race is not due to central fatigue. It is also suggested that a raise in peak twitch tension is not necessarily associated with enhanced neuromuscular function.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-2003-39088 | DOI Listing |
Eur J Appl Physiol
January 2025
College of Kinesiology, University of Saskatchewan, Saskatoon, SK, Canada.
Resistance training (RT) load and volume are considered crucial variables to appropriately prescribe and manage for eliciting the targeted acute responses (i.e., minimizing neuromuscular fatigue) and chronic adaptations (i.
View Article and Find Full Text PDFJ Neuroeng Rehabil
January 2025
Department of BioMechanical Engineering, Delft University of Technology, Mekelweg 2, Delft, 2628 CD, South-Holland, The Netherlands.
Duchenne Muscular Dystrophy (DMD) progressively leads to loss of limb function due to muscle weakness. The incurable nature of the disease shifts the focus to improving quality of life, including assistive supports to improve arm function. Over time, the passive joint impedance (Jimp) of people with DMD increases.
View Article and Find Full Text PDFCell Death Discov
January 2025
Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
The neuromuscular junction (NMJ) is essential for transmitting signals from motor neurons (MNs) to skeletal muscles (SKMs), and its dysfunction can lead to severe motor disorders. However, our understanding of the NMJ is limited by the absence of accurate human models. Although human induced pluripotent stem cell (iPSC)-derived models have advanced NMJ research, their application is constrained by challenges such as limited differentiation efficiency, lengthy generation times, and cryopreservation difficulties.
View Article and Find Full Text PDFBMJ Open
January 2025
College of Medicine and Dentistry, James Cook University, Queensland Research Centre for Peripheral Vascular Disease, Townsville, Queensland, Australia.
Introduction: Patients with peripheral artery disease (PAD) can experience intermittent claudication, which limits walking capacity and the ability to undertake daily activities. While exercise therapy is an established way to improve walking capacity in people with PAD, it is not feasible in all patients. Neuromuscular electrical stimulation (NMES) provides a way to passively induce repeated muscle contractions and has been widely used as a therapy for chronic conditions that limit functional capacity.
View Article and Find Full Text PDFLancet Neurol
February 2025
Department of Neurology, International University of Health and Welfare, Narita, Japan.
Background: Evidence from preclinical studies suggests that IL-6 signalling has the potential to modulate immunopathogenic mechanisms upstream of autoantibody effector mechanisms in patients with generalised myasthenia gravis. We aimed to assess the safety and efficacy of satralizumab, a humanised monoclonal antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis.
Methods: LUMINESCE was a randomised, double-blind, placebo-controlled, multicentre, phase 3 study at 105 sites, including hospitals and clinics, globally.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!